# Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

> **NCT02605954** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 275 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** E/C/F/TAF
- **DRUG:** ABC/3TC
- **DRUG:** Third Antiretroviral Agent

## Key facts

- **NCT ID:** NCT02605954
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-18
- **Primary completion:** 2017-06-14
- **Final completion:** 2018-01-24
- **Target enrollment:** 275 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02605954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02605954, "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02605954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*